|

Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • RAS-mutated1
  • MSS/pMMR1
  • First-Line1
  • Oxaliplatin1
  • Tislelizumab1

Other1 trial

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.